OraSure Technologies (NASDAQ:OSUR) had its price objective hosited by Jefferies Group from $8.00 to $9.00 in a report released on Friday, Analyst Ratings Network.com reports.
OraSure Technologies (NASDAQ:OSUR) opened at 6.99 on Friday. OraSure Technologies has a 52-week low of $3.75 and a 52-week high of $7.95. The stock’s 50-day moving average is $6.51 and its 200-day moving average is $5.22. The company’s market cap is $388.7 million.
OraSure Technologies (NASDAQ:OSUR) last announced its earnings results on Wednesday, November 6th. The company reported ($0.03) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.10) by $0.07. The company had revenue of $24.70 million for the quarter, compared to the consensus estimate of $24.21 million. During the same quarter in the previous year, the company posted ($0.04) earnings per share. The company’s revenue for the quarter was up 11.8% on a year-over-year basis. Analysts expect that OraSure Technologies will post $-0.37 EPS for the current fiscal year.
OSUR has been the subject of a number of other recent research reports. Analysts at Stephens downgraded shares of OraSure Technologies from an overweight rating to an equal weight rating in a research note to investors on Thursday, November 7th. Separately, analysts at Cowen and Company raised their price target on shares of OraSure Technologies from $6.60 to $8.00 in a research note to investors on Friday, October 4th. They now have an outperform rating on the stock. Finally, analysts at Raymond James upgraded shares of OraSure Technologies from a market perform rating to an outperform rating in a research note to investors on Thursday, September 19th. They now have a $8.00 price target on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. OraSure Technologies currently has an average rating of Buy and a consensus target price of $8.27.
OraSure Technologies, Inc, is engaged in development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using the Company’s oral fluid technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.